Cancer drug shows promise in Parkinson’s disease safety trial
A small clinical trial of nilotinib in people with Parkinson’s disease finds that the cancer drug is reasonably safe and holds promise as a therapy.
View original article
Contributor:
A small clinical trial of nilotinib in people with Parkinson’s disease finds that the cancer drug is reasonably safe and holds promise as a therapy.
View original article
Contributor: